Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

Wyeth

Status and phase: Withdrawn; Phase 1

Conditions: Schizophrenia

Treatments: Drug: NSA-789; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00892021

3230A1-1003

Details and patient eligibility

About

This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Men or women of non childbearing potential (WONCBP) aged 18 to 50 years, inclusive.
• Currently under the care of a physician for psychiatric illness.
• Clinical diagnosis of schizophrenia or schizo affective disorder in the opinion of the study psychiatrist based on review of all available clinical data.

Exclusion:

• Any unstable medical or psychiatric condition, which may prevent the successful and safe completion of the study.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups, including a placebo group

NSA-789

Experimental group

Description:

Active study drug

Treatment:

Drug: NSA-789

Placebo

Placebo Comparator group

Description:

Inactive study drug

Treatment:

Drug: Placebo